Update on the Management of Aspirin-Exacerbated Respiratory Disease

DSpace/Manakin Repository

Update on the Management of Aspirin-Exacerbated Respiratory Disease

Citable link to this page


Title: Update on the Management of Aspirin-Exacerbated Respiratory Disease
Author: Buchheit, Kathleen M.; Laidlaw, Tanya M.

Note: Order does not necessarily reflect citation order of authors.

Citation: Buchheit, Kathleen M., and Tanya M. Laidlaw. 2016. “Update on the Management of Aspirin-Exacerbated Respiratory Disease.” Allergy, Asthma & Immunology Research 8 (4): 298-304. doi:10.4168/aair.2016.8.4.298. http://dx.doi.org/10.4168/aair.2016.8.4.298.
Full Text & Related Files:
Abstract: Aspirin-exacerbated respiratory disease (AERD) is an adult-onset upper and lower airway disease consisting of eosinophilic nasal polyps, asthma, and respiratory reactions to cyclooxygenase 1 (COX-1) inhibitors. Management includes guideline-based treatment of asthma and sinus disease, avoidance of COX-1 inhibitors, and for some patients aspirin desensitization followed by high-dose aspirin therapy. Despite this, many patients have inadequately controlled symptoms and require multiple sinus surgeries. In this review, we discuss the current standard approaches to the management of AERD, and we introduce several therapeutics under development that may hold promise for the treatment of AERD.
Published Version: doi:10.4168/aair.2016.8.4.298
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853506/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:27822132
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search